Therapeutische Optionen bei peritonealer Metastasierung hepatopankreatikobiliärer Tumoren und neuroendokriner Tumoren

Chicago Consensus Working Group (2020) The Chicago consensus on peritoneal surface malignancies: management of neuroendocrine tumors. Ann Surg Oncol 27:1788–1792

Caplin ME, Pavel M, Cwikla JB et al (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224–233

Ding JH, Chua TC, Al-Mohaimeed K et al (2010) Hepatocellular carcinoma peritoneal metastases: report of three cases and collective review of the literature. Ann Acad Med Singap 39:734–734

Elias D, David A, Sourrouille I et al (2014) Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intra-abdominal metastases). Surgery 155:5–12

Elias D, Goéré D, Dumont F et al (2014) Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. Eur J Cancer 50:332–340

Elias D, Sideris L, Liberale G et al (2005) Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery 137:411–416

Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600

Goéré D, Passot G, Gelli M et al (2017) Complete cytoreductive surgery plus HIPEC for peritoneal metastases from unusual cancer sites of origin: results from a worldwide analysis issue of the Peritoneal Surface Oncology Group International (PSOGI). Int J Hyperthermia 33:520–527

Hajjar R, Mercier F, Passot G et al (2022) Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for small bowel neuroendocrine tumors with peritoneal metastasis. Eur J Surg Oncol 48(7):1626–1630

Kankava K, Maisonneuve P, Mangogna A et al (2021) Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: grade, mesenteric tumour deposits and emerging novelties. J Neuroendocrinol 33:e13000

Kianmanesh R, Ruszniewski P, Rindi G et al (2010) ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology 91:333–340

Lee GW, Kang JH, Kim HG et al (2006) Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma. Am J Clin Oncol 29:127–131

Leigh N, Solomon D, Pletcher E et al (2020) Is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy indicated in hepatobiliary malignancies? World J Surg Oncol 18:124

Lewis A, Raoof M, Ituarte PHG et al (2019) Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment. Ann Surg 270:1131–1137

Lin CC, Liang HP, Lee HS et al (2009) Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis. J Gastroenterol Hepatol 24:815–820

Madani A, Thomassen I, Van Gestel Y et al (2017) Peritoneal metastases from gastroenteropancreatic neuroendocrine tumors: incidence, risk factors and prognosis. Ann Surg Oncol 24:2199–2205

McEntee GP, Nagorney DM, Kvols LK et al (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108:1091–1096

Mehta S, Schwarz L, Spiliotis J et al (2018) Is there an oncological interest in the combination of CRS/HIPEC for peritoneal carcinomatosis of HCC? Results of a multicenter international study. Eur J Surg Oncol 44:1786–1792

Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61–72

Norlen O, Stalberg P, Oberg K et al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36:1419–1431

Quaedvlieg PF, Visser O, Lamers CB et al (2001) Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12:1295–1300

Raj N, Reidy-Lagunes D (2016) Systemic therapies for advanced pancreatic neuroendocrine tumors. Hematol Oncol Clin North Am 30:119–133

Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513

Rijken A, Bakkers C, Van Erning FN et al (2021) Incidence, treatment, and survival of synchronous peritoneal metastases in pancreatic cancer: update of a nationwide cohort. Pancreas 50:827–833

Sarmiento JM, Heywood G, Rubin J et al (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37

Spiliotis J, Nikolaou G, Kopanakis N et al (2017) Hepatocellular carcinoma peritoneal metastasis: role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Gulf J Oncolog 1:20–23

Strosberg J, El-Haddad G, Wolin E et al (2017) Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 376:125–135

Takeda T, Sasaki T, Mie T et al (2021) Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Pancreatology 21:903–911

Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

Van Gestel YR, Thomassen I, Lemmens VE et al (2014) Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 40:963–969

Vasseur B, Cadiot G, Zins M et al (1996) Peritoneal carcinomatosis in patients with digestive endocrine tumors. Cancer 78:1686–1692

Woltering EA, Voros BA, Beyer DT et al (2017) Aggressive surgical approach to the management of neuroendocrine tumors: a report of 1,000 surgical cytoreductions by a single institution. J Am Coll Surg 224:434–447

Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968–977